Adverse reaction report
MENU
2025.03.26
SinoT and Kalbe Farma have forged a partnership to jointly explore the Southeast Asian market.
Read More
NMPA approves SinoT’s ANDA application for Dapagliflozin and Metformin Hydrochloride Extended-release Tablet
Haimen Pharma passed SFDA inspection
2024.07.03
Haimen Pharma passed PMDA inspection
2024.07.02
SinoT passed FDA cGMP inspection with no action indicated(NAI)
2024.07.01
NMPA approves SinoT’s ANDA application for Olaparib Tablet
2024.01.23
Health Canada approves SinoT’s generic drug Posaconazole delayed-release tablets (100mg)
2023.11.02
On August 8, 2023, U.S. Food and Drug Administration(FDA)tentatively approved SinoT’s ANDA application for Tofacitinib Extended Release Tablet (ANDA #216001).
2023.06.05
Recently,Food and Drug Administration (FDA) approved SinoT’s ANDA(# 214496)application for PREGABALIN EXTENDED-RELEASE TABLETS(82.5 mg, 165 mg, and 330 mg)
Shanghai Head Office
86 21-6881-9009
99 Haike Road, Bldg. 3, 1st Flr., Pudong District Shanghai 201210, P.R. China
Manufacturing Site in Jiangsu
86 513-8122-1988
No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province
Focus on us
Copyright © 2014-2022 SINOTHERAPEUTICS.COM ICP:13048014-1 Powered by Yongsy
Privacy Legal